Emerging Novel Therapies for Heart Failure
Anthony M Szema1, Sophia Dang2, Jonathan C Li3
1Department of Technology and Society, College of Engineering and Applied Sciences, Stony Brook University, Stony Brook, NY, USA. ; Department of Occupational Medicine, Preventive Medicine, and Epidemiology, Hofstra North Shore-LIJ School of Medicine, Hofstra University, Hempstead, NY, USA. ; The Stony Brook Medicine SUNY, Stony Brook Internal Medicine Residency Program, John T. Mather Memorial Hospital, Port Jefferson, NY, USA. ; Three Village Allergy and Asthma, PLLC South Setauket, NY, USA.
Clinical Medicine Insights. Cardiology
|October 30, 2015
Summary
Novel therapies are needed for heart failure. Vasoactive Intestinal Peptide (VIP) shows protective effects and may be a potential treatment for acute heart failure, especially with new stabilization methods.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Heart failure, including ejection fraction-preserved heart failure, has high mortality and morbidity rates.
- Current knowledge of heart failure necessitates novel therapeutic approaches.
- Existing treatments for heart failure require augmentation with innovative strategies.
Purpose of the Study:
- To review current heart failure therapies.
- To explore emerging treatments for heart failure.
- To investigate the potential of Vasoactive Intestinal Peptide (VIP) as a novel therapy for acute heart failure.
Main Methods:
- Review of existing heart failure treatments.
- Exploration of novel therapeutic agents, including VIP.
- Analysis of VIP knockout mouse models to understand gene dysregulation in heart failure.
- Examination of VIP's effects on coronary dilation in human subjects.
Main Results:
- VIP knockout mice exhibit dysregulation in key heart failure genes related to force generation, energy production, calcium cycling, and transcriptional regulation.
- VIP administration induces coronary dilation in human subjects.
- Elevated VIP levels in heart failure patients suggest a potential endogenous protective role.
- Development of elastin polymers offers a method to stabilize VIP and prevent degradation.
Conclusions:
- VIP demonstrates cardioprotective properties and warrants further investigation as a potential treatment for acute heart failure.
- Stabilization of VIP using elastin polymers may enhance its therapeutic efficacy.
- VIP represents a promising candidate to address the unmet need for effective acute heart failure treatments.
Keywords:
VIPgenesheart failureivbradineknockout micenovel therapiessacubitrivasoactive intestinal peptideMore Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
568
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
568
01:30Heart Failure V: Medical Management
532
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
532
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K